One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

@article{Bunck2009OneYearTW,
  title={One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients},
  author={Mathijs C Bunck and Michaela Diamant and Anja Corn{\'e}r and Bjorn Eliasson and Jaret L. Malloy and Rimma M. Shaginian and Wei Deng and David M. Kendall and Marja-Riitta Taskinen and Ulf Smith and Hannele Yki-J{\"a}rvinen and R. Heine},
  journal={Diabetes Care},
  year={2009},
  volume={32},
  pages={762 - 768}
}
OBJECTIVE Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in beta-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp-derived measures of beta-cell function, glycemic control, and body weight. RESEARCH DESIGN AND METHODS Sixty-nine metformin-treated… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 165 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial

  • B Zinman, BJ Hoogwerf, +5 authors RG. Brodows
  • Ann Intern Med
  • 2007

Similar Papers

Loading similar papers…